The Cooper Companies, Inc. (COO)
- Previous Close
90.41 - Open
90.92 - Bid 90.40 x 100
- Ask 90.46 x 200
- Day's Range
90.28 - 90.99 - 52 Week Range
75.93 - 104.07 - Volume
1,173,819 - Avg. Volume
1,128,811 - Market Cap (intraday)
17.972B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
61.93 - EPS (TTM)
1.46 - Earnings Date May 30, 2024
- Forward Dividend & Yield 0.02 (0.02%)
- Ex-Dividend Date Jul 26, 2023
- 1y Target Est
108.36
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
www.coopercos.com15,000
Full Time Employees
October 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: COO
Performance Overview: COO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COO
Valuation Measures
Market Cap
17.97B
Enterprise Value
20.61B
Trailing P/E
62.03
Forward P/E
25.71
PEG Ratio (5yr expected)
11.17
Price/Sales (ttm)
4.92
Price/Book (mrq)
2.34
Enterprise Value/Revenue
5.62
Enterprise Value/EBITDA
23.03
Financial Highlights
Profitability and Income Statement
Profit Margin
7.93%
Return on Assets (ttm)
2.69%
Return on Equity (ttm)
3.87%
Revenue (ttm)
3.67B
Net Income Avi to Common (ttm)
290.8M
Diluted EPS (ttm)
1.46
Balance Sheet and Cash Flow
Total Cash (mrq)
135.2M
Total Debt/Equity (mrq)
39.68%
Levered Free Cash Flow (ttm)
137.98M
Research Analysis: COO
Analyst Price Targets
Fair Value
Analyst Recommendations
Earnings
Research Reports: COO
COO: Lowering target price to $95.00
COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $95.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetAnalyst Report: The Cooper Companies, Inc.
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
RatingNeutralPrice TargetCOO: Raising target price to $104.00
COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $104.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetCOO: Lowering target price to $103.00
COOPER COS INC/THE has an Investment Rating of HOLD; a target price of $103.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingNeutralPrice Target